Christophe Piketty

5.6k total citations · 1 hit paper
116 papers, 3.7k citations indexed

About

Christophe Piketty is a scholar working on Infectious Diseases, Epidemiology and Dermatology. According to data from OpenAlex, Christophe Piketty has authored 116 papers receiving a total of 3.7k indexed citations (citations by other indexed papers that have themselves been cited), including 49 papers in Infectious Diseases, 39 papers in Epidemiology and 34 papers in Dermatology. Recurrent topics in Christophe Piketty's work include HIV/AIDS drug development and treatment (38 papers), Dermatology and Skin Diseases (33 papers) and HIV Research and Treatment (32 papers). Christophe Piketty is often cited by papers focused on HIV/AIDS drug development and treatment (38 papers), Dermatology and Skin Diseases (33 papers) and HIV Research and Treatment (32 papers). Christophe Piketty collaborates with scholars based in France, United States and Germany. Christophe Piketty's co-authors include Michel D. Kazatchkine, Laurence Weiss, Dominique Batisse, Patrick Bruneval, Laurent Bélec, Dominique Costagliola, Isabelle Heard, Teresa M. Darragh, Joel M. Palefsky and Maria Da Costa and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Christophe Piketty

111 papers receiving 3.6k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Trial of Nemolizumab in Moderate-to-Severe Prurigo Nodularis

2020 173 citations Sonja Ständer, Gil Yosipovitch et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Christophe Piketty France	30	1.6k	1.5k	1.2k	643	606	116	3.7k
Michaela Lucas Australia	34	501 0.3×	1.4k 0.9×	607 0.5×	177 0.3×	130 0.2×	140	4.2k
A Vierucci Italy	34	442 0.3×	1000 0.6×	317 0.3×	627 1.0×	314 0.5×	160	3.4k
Stefania Piconi Italy	25	821 0.5×	616 0.4×	1.2k 1.0×	219 0.3×	75 0.1×	62	2.5k
Laurence Weiss France	42	1.9k 1.2×	1.3k 0.8×	2.5k 2.2×	45 0.1×	257 0.4×	140	5.6k
Allan R. Tenorio United States	22	1.0k 0.6×	424 0.3×	1.1k 0.9×	465 0.7×	58 0.1×	55	2.4k
Joseph A. Church United States	30	826 0.5×	577 0.4×	808 0.7×	97 0.2×	217 0.4×	182	3.2k
Suranjith L. Seneviratne United Kingdom	27	1.1k 0.7×	705 0.5×	63 0.1×	327 0.5×	209 0.3×	108	3.2k
Israel Yust Israel	21	1.1k 0.7×	642 0.4×	770 0.7×	70 0.1×	172 0.3×	81	2.5k
E. McKinnon Australia	25	1.3k 0.8×	717 0.5×	1.1k 1.0×	80 0.1×	263 0.4×	90	2.9k
Marijke Roos Netherlands	37	2.3k 1.4×	1.4k 0.9×	3.3k 2.8×	35 0.1×	161 0.3×	56	5.4k

Countries citing papers authored by Christophe Piketty

Since Specialization

Citations

This map shows the geographic impact of Christophe Piketty's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christophe Piketty with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christophe Piketty more than expected).

Fields of papers citing papers by Christophe Piketty

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christophe Piketty. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christophe Piketty. The network helps show where Christophe Piketty may publish in the future.

Co-authorship network of co-authors of Christophe Piketty

This figure shows the co-authorship network connecting the top 25 collaborators of Christophe Piketty. A scholar is included among the top collaborators of Christophe Piketty based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christophe Piketty. Christophe Piketty is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ständer, Sonja, Sarina B. Elmariah, Shawn G. Kwatra, et al.. (2025). Rapid improvement of itch with nemolizumab in atopic dermatitis and prurigo nodularis phase 3 studies. Journal of the European Academy of Dermatology and Venereology.

Morgan, Christopher Ll., Sonja Ständer, Zarif K. Jabbar‐Lopez, et al.. (2025). Epidemiology of prurigo nodularis: An analysis of global trends from 1998 to 2023. Clinical Epidemiology and Global Health. 33. 102003–102003. 2 indexed citations

Stein‐Gold, Linda, Diamant Thaçi, Andrew Pink, et al.. (2024). 733 - Nemolizumab elicits fast itch response in atopic dermatitis within 2 days: a post hoc analysis of ARCADIA 1 and 2 data. British Journal of Dermatology. 191(Supplement_2).

Kwatra, Shawn G., Jorge Puelles, Varsha Parthasarathy, et al.. (2024). Prevalence of prurigo nodularis in the United States. JAAD International. 18. 134–136. 3 indexed citations

Yosipovitch, Gil, Sonja Ständer, Martin Metz, et al.. (2024). 672 - Nemolizumab monotherapy improves itch, sleep disturbance, and skin lesions in patients with moderate-to-severe prurigo nodularis: Pooled analyses from OLYMPIA 1 and OLYMPIA 2 phase 3 studies. British Journal of Dermatology. 191(Supplement_2). 1 indexed citations

Kwatra, Shawn G., et al.. (2023). Patient Perspectives on Living With Severe Prurigo Nodularis. JAMA Dermatology. 159(11). 1205–1205. 7 indexed citations

Deng, Junwen, Varsha Parthasarathy, Hannah Cornman, et al.. (2023). Modulation of Neuroimmune and Epithelial Dysregulation in Patients With Moderate to Severe Prurigo Nodularis Treated With Nemolizumab. JAMA Dermatology. 159(9). 977–977. 10 indexed citations

Tsoi, Lam C., Paul Fogel, Xianying Xing, et al.. (2021). LB817 Transcriptomic characterization of Prurigo Nodularis and the therapeutic response to Nemolizumab.. Journal of Investigative Dermatology. 141(9). B27–B27. 1 indexed citations

Ständer, Sonja, Gil Yosipovitch, Franz J. Legat, et al.. (2020). Trial of Nemolizumab in Moderate-to-Severe Prurigo Nodularis. New England Journal of Medicine. 382(8). 706–716. 173 indexed citations breakdown →

10.

Assoumou, Lambert, Laurence Weiss, Christophe Piketty, et al.. (2015). A low HIV-DNA level in peripheral blood mononuclear cells at antiretroviral treatment interruption predicts a higher probability of maintaining viral control. AIDS. 29(15). 2003–2007. 61 indexed citations

11.

Môle, B, Florence Gillaizeau, Isabelle Pierre, et al.. (2011). Polyacrylamide Hydrogel Injection in the Management of Human Immunodeficiency Virus-Related Facial Lipoatrophy: Results of the LIPOPHILL Open-Label Study. AIDS Research and Human Retroviruses. 28(3). 251–258. 13 indexed citations

12.

Angelakis, Emmanouil, Cristina Socolovschi, Chantal Sobas, et al.. (2010). Murine Typhus as a Cause of Fever in Travelers From Tunisia and Mediterranean Areas. Journal of Travel Medicine. 17(5). 310–315. 27 indexed citations

13.

Yazdanpanah, Yazdan, Catherine Fagard, Diane Descamps, et al.. (2009). High Rate of Virologic Suppression with Raltegravir plus Etravirine and Darunavir/Ritonavir among Treatment‐Experienced Patients Infected with Multidrug‐Resistant HIV: Results of the ANRS 139 TRIO Trial. Clinical Infectious Diseases. 49(9). 1441–1449. 175 indexed citations

14.

Benhamou, Yves, Hervé Fleury, Pascale Trimoulet, et al.. (2006). Anti-hepatitis B virus efficacy of tenofovir disoproxil fumarate in HIV-infected patients. Hepatology. 43(3). 548–555. 121 indexed citations

15.

Piketty, Christophe & Michel D. Kazatchkine. (2005). Human papillomavirus-related cervical and anal disease in HIV-infected individuals in the era of highly active antiretroviral therapy. Current HIV/AIDS Reports. 2(3). 140–145. 21 indexed citations

16.

Launay, Odile, Laurent Roudière, Narjis Boukli, et al.. (2004). Assessment of Cetirizine, an Antihistamine, to Prevent Cutaneous Reactions to Nevirapine Therapy: Results of the Viramune‐Zyrtec Double‐Blind, Placebo‐Controlled Trial. Clinical Infectious Diseases. 38(8). e66–e72. 18 indexed citations

17.

Bélec, Laurent, Jérôme LeGoff, Ali Si‐Mohamed, et al.. (2002). Sustained high proportion of zidovudine‐resistant HIV variants despite prolonged substitution of zidovudine by other nucleoside reverse transcriptase inhibitors. Journal of Medical Virology. 68(1). 1–6. 2 indexed citations

18.

Andréoletti, Laurent, Laurence Weiss, Ali Si‐Mohamed, et al.. (2002). Multidrug-Resistant HIV-1 RNA and Proviral DNA Variants Harboring New Dipeptide Insertions in the Reverse Transcriptase pol Gene. JAIDS Journal of Acquired Immune Deficiency Syndromes. 29(1). 102–104. 6 indexed citations

19.

Landau, Alain, Dominique Batisse, Christophe Piketty, et al.. (2001). Long-term efficacy of combination therapy with interferon-α2b and ribavirin for severe chronic hepatitis C in HIV-infected patients. AIDS. 15(16). 2149–2155. 77 indexed citations

20.

Bourquelot, Priscille, et al.. (1993). [Hemophagocytic syndrome in HIV infection].. PubMed. 22(26). 1217–20. 23 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact